Browse Category

NYSE:SPHR News 25 December 2025

Pudgy Penguins Lights Up the Las Vegas Sphere for Christmas as PENGU Reacts — Branding vs Technology in Crypto’s 2025 Reality

Pudgy Penguins Lights Up the Las Vegas Sphere for Christmas as PENGU Reacts — Branding vs Technology in Crypto’s 2025 Reality

LAS VEGAS — December 25, 2025. A Web3-born brand just claimed one of the most visible advertising canvases on Earth. Pudgy Penguins—best known for its blue-chip NFT collection—has projected its animated penguin characters across the exterior of the Las Vegas Sphere during Christmas week, a move that puts the project’s IP in front of mainstream tourists rather than just crypto-native audiences. TradingView The attention has spilled into markets as well. PENGU, the ecosystem’s token often treated like a meme coin by traders, bounced off a December 24 low after the Sphere appearance—even as broader crypto trading remained muted through the
25 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop